Targeting the PI3K-Akt pathway in kidney cancer

Jin Young Park, Pei Yin Lin, Robert H Weiss

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Kidney cancer, or renal cell carcinoma, is a relatively rare malignancy but is metastatic at diagnosis in a third of patients; metastatic disease has a dismal prognosis. Conventional chemotherapy has been woefully inadequate, thus novel targets for 'designer' therapies are being actively evaluated. The PI3K-Akt signaling cascade, owing to its dual role in both survival and mitogenic signaling, is in theory an ideal therapeutic target for this disease, but may also represent its fatal flaw. Thus, largely due to toxicity issues, no PI3K or Akt inhibitors are currently ready for clinical application. In this review, we discuss PI3K-Akt inhibitors as well as inhibitors of pathways and targets both immediately up- and downstream of this cascade, many of which show promise in the clinic.

Original languageEnglish (US)
Pages (from-to)863-870
Number of pages8
JournalExpert Review of Anticancer Therapy
Issue number6
StatePublished - Jun 2007


  • Akt
  • Inhibitors
  • PI3K
  • Receptor tyrosine kinase
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Targeting the PI3K-Akt pathway in kidney cancer'. Together they form a unique fingerprint.

Cite this